CMS' proposed 340B reimbursement cut—who wins, and who loses?

The Centers for Medicare and Medicaid Services’ recent proposal to overhaul Medicare’s reimbursement rates for 340B drugs will be a drag on many large hospitals and those treating a disproportionat | Disproportionate share hospitals are expected to see a 5.8% net reduction in OPPS revenue under the proposal, while for-profits are expecting a 7.4% net increase, KFF highlighted in a recent analysis of CMS projections.